Current Research: I have an interest in the mechanisms of acute lung inflammation. In that light, I have worked for several years refining a mouse model of the resolution phase of acute lung inflammation. The experiments conducted called for very detailed work with flow cytometric techniques. The clinical research topics in which I have worked mirrored the experiments in the mouse model. As a critical care physician, I have been involved in many aspects of clinical study design and administration. I have had the opportunity to be involved in many multicenter studies that span Phase I through Phase IV FDA approval of therapeutic agents. Recent Publications: Morris PE. Critical Care Professionalism in the Age of Pay-for-Performance: From ICUs to Outpatient Critical Care Clinics. Am J Crit Care. 2007 May;16(3):200-203. Morris PE, Herridge MS. Early intensive care unit mobility: future directions. Crit Care Clin. 2007 Jan;23(1):97-110. Review. Morris PE. Moving our critically ill patients: mobility barriers and benefits. Crit Care Clin. 2007 Jan;23(1):1-20. Review. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med. 2006 Sep;34(9):2271-81. Kamath VP, Zhang J, Morris PE Jr, Babu YS. Synthesis of a potent 5'-methylthioadenosine/S-adenosylhomocysteine (MTAN) inhibitor. Bioorg Med Chem Lett. 2006 May 15;16(10):2662-5. Epub 2006 Feb 28. Publications:
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine |